<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) January 13, 1997
-------------------
BOSTON LIFE SCIENCES, INC.
--------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-6533 87-0277826
- ---------------------------- ------ -------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
incorporation or organization) File No.) of Identification No.)
31 Newbury Street, Suite 300
Boston, Massachusetts 02116
- -------------------------------- ------------
(Address of principal Zip Code
executive offices)
Registrant's telephone number, including area code (617) 425-0200
--------------------
<PAGE>
Item 5. Other Events.
-------------
On January 13, 1997, Boston Life Sciences, a company engaged in the research and
development of novel treatments for cancer, autoimmune diseases, and central
nervous system disorders, announced that the Company had filed its
Investigational New Drug ("IND") application for Altropane/TM/, and would
initiate its corporate Phase I/II clinical trial within the next few weeks.
Based on what the Company believes were encouraging results from its Physician's
Sponsored Phase I/II study at Mass. General Hospital in 1996, the Company now
plans an accelerated clinical development program. The Company's objective is
to complete the Phase I/II and Phase III trials, and contingent upon prompt
patient enrollment and satisfactory clinical results, to file for marketing
approval before the end of 1997. The Company has already begun preliminary
discussions with several potential manufacturing, distribution, and marketing
partners.
Item 7. Exhibits.
--------
The following Exhibit is filed as part of this report on Form 8-K:
99.1 Press Release, dated January 13, 1997.
2
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto authorized.
BOSTON LIFE SCIENCES, INC.
Dated: January 20, 1997 By: /s/ Joseph Hernon
--------------------
Joseph Hernon
Chief Financial Officer
3
<PAGE>
BOSTON LIFE SCIENCES, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
Exhibit No. Page
- ----------- ----
99.1 Press Release, dated January 13, 1997 5
4
<PAGE>
Exhibit 99.1
***FOR IMMEDIATE RELEASE***
BOSTON LIFE SCIENCES TO BEGIN CLINICAL TRIALS WITH ALTROPANE
Boston, MA - January 13, 1997 --Boston Life Sciences, Inc. (NASDAQ: BLSI)
announced that the Company had filed its Investigational New Drug (IND)
application for Altropane/TM/, and would initiate its corporate Phase I/II
clinical trial within the next few weeks.
"Based on the exciting and encouraging results from our Physician's Sponsored
Phase I/II study at the Mass. General Hospital last year, we have now planned an
accelerated clinical development program. Our objective is to complete our
Phase I/II and Phase III trials and, contingent upon prompt patient enrollment
and satisfactory clinical results, to file for marketing approval before the end
of 1997", stated Marc Lanser MD, Chief Scientific Officer of BLSI. Dr. Lanser
further stated that the Company had already begun preliminary discussions with
several potential manufacturing, distribution, and marketing partners.
BLSI is engaged in the research and development of novel treatments for cancer,
autoimmune diseases, and central nervous system disorders. BLSI's products in
clinical trials or in pre-clinical development include the above-mentioned
Altropane; an anti-angiogenesis factor for the treatment of solid tumors;
Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor;
THERAFECTIN/(R)/ for the treatment of Rheumatoid Arthritis; and two
transcription factors to control the expression of molecules associated with
autoimmune disease and allergies.
For additional information contact:
Marc E. Lanser, MD
Chief Scientific Officer
617-425-0200
# # #
